Gritstone bio, Inc. (GRTS)
Pre-market:
| Previous close | 2.4200 |
| Open | 2.4700 |
| Bid | 2.4600 x 3100 |
| Ask | 2.7500 x 900 |
| Day's range | 2.3900 - 2.5950 |
| 52-week range | 1.7100 - 14.4200 |
| Volume | |
| Avg. volume | 1,264,740 |
| Market cap | 179.119M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5440 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.33 |
- GlobeNewswire
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors has granted eight employees nonqualified stock options to purchase an aggregate of 67,550 shares of its common stock with an exercise price of $2.66, which is equal to the closing price of Gritstone’s common stock on June 23, 2022, the grant date of the awards.
- GlobeNewswire
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications
-- Results, which were previously pre-printed in bioRxiv, show Gritstone’s second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad neutralizing antibodies, T cell responses and offered protection against SARS-CoV-2 infection in rhesus macaques -- -- Neutralizing antibody responses were induced at up to a 10-fold lower dose than first-generation mRNA vaccines -- -- Durable protection against SARS-CoV-2 in rhesus macaques observed with the samRNA vaccine regimen supports ongo
- Simply Wall St.
Gritstone bio (NASDAQ:GRTS) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
